Thursday, June 15, 2023 12:54:47 PM
In connection with the foregoing, on June 14, 2023, the Company entered into a limited consent (the “Limited Consent”), dated as of June 14, 2023, to that certain Facility Agreement, dated as of August 9, 2022 (the “Facility Agreement”), by and among the Company, as borrower, certain of the Company’s subsidiaries from time to time party thereto as guarantors and Deerfield Partners, L.P., as agent for itself and the lenders (collectively, “Deerfield”). The Limited Consent permits the repurchase by the Company on or prior to June 16, 2023, of up to 5,000,000 shares of the Company’s Common Stock in one or more open market or negotiated purchases, in each case at price per share not to exceed $0.75. The actual timing and amount of repurchases are subject to business and market conditions, corporate and regulatory requirements, stock price, acquisition opportunities and other factors. The Limited Consent does not obligate the Company to repurchase any amount of shares, and there can be no assurance that any shares will be repurchased. The Limited Consent also grants a one-time waiver under the Facility Agreement of certain delivery of any notice requirements.
The foregoing description of the Limited Consent does not purport to be complete and is qualified in its entirety by reference to the full text of the Limited Consent, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.
Recent TOI News
- The Oncology Institute to Participate in Panel Discussion at the Leerink Healthcare Transformation Summit • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- The Oncology Institute Announces First Quarter 2024 Earnings Release Date and Conference Call • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Jordan McInerney Appointed as Chief Development Officer of The Oncology Institute • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern California • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
- The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024 • GlobeNewswire Inc. • 03/27/2024 08:05:00 PM
- MaxHealth & The Oncology Institute Expand Value-Based Care Partnership • GlobeNewswire Inc. • 03/14/2024 12:09:05 PM
- The Oncology Institute Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Conference Call • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- The Oncology Institute to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/27/2024 09:05:00 PM
- Carrum Health and The Oncology Institute Partner on Breast Cancer Treatment Model • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- WellBe Senior Medical Partners with The Oncology Institute to Extend High-Value Cancer Care Services Across Illinois and Ohio • GlobeNewswire Inc. • 01/25/2024 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/19/2024 09:00:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:46:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:38:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:16:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 12:42:59 AM
- The Oncology Institute Expands its Specialty Medication Business by Opening Pharmacy Operations in California • GlobeNewswire Inc. • 12/04/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/23/2023 02:01:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/23/2023 01:47:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/23/2023 01:37:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 12:27:35 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/17/2023 10:27:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/16/2023 09:40:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/16/2023 08:56:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 11:49:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/13/2023 10:17:43 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM